Rgenix
2010
FOUNDED
PRIVATE
STATUS
11-20
EMPLOYEES
Series C
LATEST DEAL TYPE
$40M
LATEST DEAL AMOUNT
12
INVESTORS
Description
Developer of novel cancer drugs that target key pathways in cancer progression. The company's therapies identify novel cancer targets using a microRNA based target discovery platform, enabling cancer patients to get faster cure using drugs that target using small molecules and antibodies.
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- 310 East 67th Street
- Suite 1-12
- New York, NY 10065
- United States
+1 (646) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Rgenix’s full profile, request a free trial.
Rgenix Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 09-Oct-2018 | $40M | 000.00 | 00000 | Completed | Clinical Trials - Phase 1 |
| 4. Early Stage VC (Series B) | 03-Jun-2016 | 0000 | 000.00 | 0000 | Completed | Pre-Clinical Trials |
| 3. Early Stage VC (Series A) | 31-Jul-2015 | 000 | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
| 2. Grant | 11-Aug-2014 | $200K | $2.5M | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 30-Sep-2013 | $2.5M | $2.5M | 000.00 | Completed | Pre-Clinical Trials |
Rgenix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | 00,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 13,889,841 | $0.000100 | $0.61 | $0.61 | 1x | $0.61 | 6.77% | |
| Seed | 5,869,618 | $0.000100 | $0.53 | $0.53 | 1x | $0.53 | 3.1% |
Rgenix Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lycera | Venture Capital-Backed | Ann Arbor, MI | 00 | 00000 | 00000000000 | 00000 |
| 0 00000 000000 | Accelerator/Incubator Backed | Houston, TX | 000 | 000000000000 | 000 | |
| 000000 00000000000 | Venture Capital-Backed | New York, NY | 0000 | 00000000000 | 0000 | |
| 000000 00000000 | Formerly VC-backed | Boulder, CO | 000 | 00000 | 000000 - 000 | 00000 |
| 00000000000 | Angel-Backed | Culver City, CA | 00000 | 000000000000 | 00000 |
Rgenix Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Lepu Medical | Corporation | Minority | 000 0000 | 000000 0 | ||
| Oceanpine Capital | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Oceanpine Healthcare Fund | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| WuXi AppTec | Corporation | Minority | 000 0000 | 000000 0 | ||
| Novo Holdings | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
Rgenix Executive Team (14)
2 Former Executives
You’re viewing 5 of 14 executives. Get the full list »Rgenix Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Antoine Papiernik | Sofinnova Partners | Board Member | 000 0000 | |
| David Darst | Self | Chief Operating Officer & Board Observer | 000 0000 | |
| Eric Rowinsky MD | Self | Board Member & President | 000 0000 | |
| Masoud Tavazoie Ph.D | Rgenix | Co-Founder, Board Member and Chief Executive Officer | 000 0000 | |
| Nancy Chang Ph.D | Self | Board Member | 000 0000 |
1 Former Board Member
You’re viewing 5 of 10 board members. Get the full list »